Human liver microsomal N-hydroxylation of dapsone by cytochrome P-4503A4
- PMID: 1588928
Human liver microsomal N-hydroxylation of dapsone by cytochrome P-4503A4
Abstract
One of the major routes of elimination of dapsone (4,4'-diaminodiphenylsulfone) is by N-oxidation, to produce a hydroxylamine metabolite. The specific form of cytochrome P-450 (P-450) involved in this oxidation reaction was examined in human liver microsomal preparations previously characterized with respect to their content of several known P-450 enzymes. Among five preparations, the rank order of activity for dapsone hydroxylamine formation was most well correlated with the immunochemically determined level of P-4503A4 (r = 0.94, p less than 0.03). Moreover, inhibition of microsomal oxidation was observed with antibodies specific to P-4503A, with a maximum reduction of greater than 90%, but was not produced by antibodies specific to P-4501A2, P-4502CMP, or P-4502E1. Prior incubation of microsomes with gestodene (100 microM) or troleandomycin (20 microM), known selective mechanism-based inhibitors of P-4503A enzymes (in the presence of NADPH), led to 75% and 40% reductions in catalytic activity, respectively. In contrast, preincubation with increasing concentrations of alpha-naphthoflavone, a known activator of P-4503A4, increased dapsone N-hydroxylation in a concentration-dependent manner, with 5-fold activation being observed at 50 microM alpha-naphthoflavone. Finally, P-4503A4 isolated from human liver microsomes and cDNA-expressed P-4503A4 (in yeast) were both able to catalyze dapsone N-hydroxylation, with the latter preparation exhibiting a 3-fold activation in the presence of 100 microM alpha-naphthoflavone. Collectively, these findings demonstrate that N-oxidation of dapsone in human liver is predominantly mediated by P-4503A4, and they suggest that quantitative measurement of this metabolic pathway in vivo might serve as an index of the activity of this enzyme.
Similar articles
-
Roles of human liver cytochrome P4502C and 3A enzymes in the 3-hydroxylation of benzo(a)pyrene.Cancer Res. 1992 Apr 1;52(7):1868-74. Cancer Res. 1992. PMID: 1551116
-
Oxidation of 17 alpha-ethynylestradiol by human liver cytochrome P-450.Mol Pharmacol. 1988 May;33(5):500-8. Mol Pharmacol. 1988. PMID: 3285175
-
Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes.Mol Pharmacol. 1994 Sep;46(3):568-77. Mol Pharmacol. 1994. PMID: 7935340
-
Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P-450 3A4. An explanation of the variable elimination clearance.Anesthesiology. 1992 Sep;77(3):467-74. doi: 10.1097/00000542-199209000-00011. Anesthesiology. 1992. PMID: 1519785 Review.
-
Metabolism of 17 alpha-ethynylestradiol in humans.Life Sci. 1990;47(22):1981-8. doi: 10.1016/0024-3205(90)90431-p. Life Sci. 1990. PMID: 2273938 Review.
Cited by
-
Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.Clin Pharmacokinet. 2005;44(3):279-304. doi: 10.2165/00003088-200544030-00005. Clin Pharmacokinet. 2005. PMID: 15762770 Review.
-
In vitro analysis of metabolic predisposition to drug hypersensitivity reactions.Clin Exp Immunol. 1995 Jan;99(1):1-6. doi: 10.1111/j.1365-2249.1995.tb03463.x. Clin Exp Immunol. 1995. PMID: 7813099 Free PMC article. Review.
-
Formation of potentially toxic metabolites of drugs in reactions catalyzed by human drug-metabolizing enzymes.Arch Toxicol. 2024 Jun;98(6):1581-1628. doi: 10.1007/s00204-024-03710-9. Epub 2024 Mar 23. Arch Toxicol. 2024. PMID: 38520539 Free PMC article. Review.
-
Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations.Clin Pharmacokinet. 1997 Mar;32(3):194-209. doi: 10.2165/00003088-199732030-00003. Clin Pharmacokinet. 1997. PMID: 9084959 Review.
-
N-Hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of haemotoxicity.Br J Clin Pharmacol. 1995 Dec;40(6):531-8. doi: 10.1111/j.1365-2125.1995.tb05797.x. Br J Clin Pharmacol. 1995. PMID: 8703658 Free PMC article.